Protocol for a randomized controlled trial of intensive blood pressure control on cardiovascular risk reduction in patients with atrial fibrillation: Rationale and design of the CRAFT trial
Chao Jiang,Zhiyan Wang,Xin Du,Yufeng Wang,Mingyang Gao,Zhaoxu Jia,Zhongyi Chai,Zhiyun Yang,Chi Wang,Liu He,Rong Hu,Qiang Lv,Jiahui Wu,Xu Li,Changqi Jia,Rong Han,Hisatomi Arima,Xia Wang,Bruce Neal,Anthony Rodgers,Graham S Hillis,Anushka Patel,Qiang Li,Jianzeng Dong,Craig S Anderson,Changsheng Ma
DOI: https://doi.org/10.1016/j.ahj.2024.08.008
2024-09-07
Abstract:Background: Co-morbid hypertension is strong predictor of adverse cardiovascular (CV) outcomes in patients with atrial fibrillation (AF) but the optimal target for blood pressure (BP) control in this patient population has not been clearly defined. Methods: The Cardiovascular Risk reduction in patients with Atrial Fibrillation Trial (CRAFT) is an investigator-initiated and conducted, international, multicenter, open-label, parallel-group, blinded outcome assessed, randomized controlled trial of intensive BP control in patients with AF. The aim is to determine whether intensive BP control (target home systolic blood pressure [SBP] <120 mmHg) is superior to standard BP control (home SBP <135 mmHg) on the hierarchical composite outcome of time to CV death, number of stroke events, time to the first stroke, number of myocardial infarction (MI) events, time to the first MI, number of heart failure hospitalization (HFH) events, and time to the first HFH. A sample size of 1,675 patients is estimated to provide 80% power to detect a win-ratio of 1.50 for intensive versus standard BP control on the primary composite outcome. Study visits are conducted at 1, 2, 3, and 6 months postrandomization, and every 6 months thereafter during the study. Conclusions: This clinical trial aims to provide reliable evidence of the effects of intensive BP control in patients with AF. Trial registration: The trial is registered at ClinicalTrials.gov (NCT04347330).